Grant: Discovery Grants Program - Individual
University of Calgary
$36,000.00
Combating Multidrug Resistence: New Chemical Strategies to Target Bacterial Virulence Factors
EF 2024-25
Résumé
The recent COVID-19 pandemic has caused one of the great losses of lives in human history and shut down the world for several years. Today, while the world is still in high alert to a possible coming back by other mutant strains of SARS-COV-2 virus, we continue facing other imminent threats, notably those caused by multi-drug-resistant (MDR) bacteria. During recent years, reports on antimicrobial drug resistance have steadily increased at an alarming rate and this has spread into most families of bacteria. What making things even more dire is the unprecedented shortage of antibacterial arsenal both in human hands and in the development pipeline. This situation is further aggravated by a lack of major investment from major players in the pharmaceutical industries because of economic concern. Thus, there is an urgent need for all other interested parties to step up research to address this imminent global challenge. Although conventional antibiotics can initially treat an infection with success, their uses are also directly linked to the development of bacterial drug resistance. This is because of their mechanistic actions that unintentionally select those drug-resistant strains to survive. Additionally, conventional antibiotics are generally non-selective, capable of killing many gut bacterial populations with little selectivity. Thus, their use can cause a major alteration of gut microbiome populations, providing opportunities for those that contain drug-resistant genes to flourish. Addressing MDR requires more selective and less invasive approaches that target only pathogenic bacterial strains; long-term solutions should aim at reducing the selective pressure for a bacterium to develop mutations. Vaccination is a powerful approach to address MDR, as induced immune response is usually very precise to the antigen structure. Resistance to vaccines has been rare. In this grant, we propose to develop the chemical syntheses for a group of unique bacterial carbohydrates that are found at the flagella of many strains of bacteria; structurally they are very distinct from human glycans, thus they meet the criteria to be used as antigens in vaccines. More importantly, there exist significant differences in structures of these flagellar carbohydrates between different strains of bacteria or different serotypes, making the studies of these group of carbohydrates extremely valuable. Alternatively, we propose to develop amphiphilic supramolecular systems capable of self-assembly into micelles; such systems have a particular carbohydrate sequence incoporated thus can only be recognized by specific bacterial stains because of their fimbrial lectins. Such systems can be used in antiadhesin therapies to block bacterial colonizations with high selectivity; they can also be used as targeted drug delivery system to empower conventional broad spectrum antibiotics to achieve a selectivity.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2024-04267
Name nom
Ling, Chang-Chun
Department département
Chemistry
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Combating Multidrug Resistence: New Chemical Strategies to Target Bacterial Virulence Factors
Keywords
organic synthesis; synthetic methodology; carbohydrate chemistry; glycosylations; chemoenzymatic synthesis; bacterial surface glycans; bacterial adhesins; self-assembled systems; characterization of drug delivery systems; antibacterial strategies
Application summary
The recent COVID-19 pandemic has caused one of the great losses of lives in human history and shut down the world for several years. Today, while the world is still in high alert to a possible coming back by other mutant strains of SARS-COV-2 virus, we continue facing other imminent threats, notably those caused by multi-drug-resistant (MDR) bacteria. During recent years, reports on antimicrobial drug resistance have steadily increased at an alarming rate and this has spread into most families of bacteria. What making things even more dire is the unprecedented shortage of antibacterial arsenal both in human hands and in the development pipeline. This situation is further aggravated by a lack of major investment from major players in the pharmaceutical industries because of economic concern. Thus, there is an urgent need for all other interested parties to step up research to address this imminent global challenge. Although conventional antibiotics can initially treat an infection with success, their uses are also directly linked to the development of bacterial drug resistance. This is because of their mechanistic actions that unintentionally select those drug-resistant strains to survive. Additionally, conventional antibiotics are generally non-selective, capable of killing many gut bacterial populations with little selectivity. Thus, their use can cause a major alteration of gut microbiome populations, providing opportunities for those that contain drug-resistant genes to flourish. Addressing MDR requires more selective and less invasive approaches that target only pathogenic bacterial strains; long-term solutions should aim at reducing the selective pressure for a bacterium to develop mutations. Vaccination is a powerful approach to address MDR, as induced immune response is usually very precise to the antigen structure. Resistance to vaccines has been rare. In this grant, we propose to develop the chemical syntheses for a group of unique bacterial carbohydrates that are found at the flagella of many strains of bacteria; structurally they are very distinct from human glycans, thus they meet the criteria to be used as antigens in vaccines. More importantly, there exist significant differences in structures of these flagellar carbohydrates between different strains of bacteria or different serotypes, making the studies of these group of carbohydrates extremely valuable. Alternatively, we propose to develop amphiphilic supramolecular systems capable of self-assembly into micelles; such systems have a particular carbohydrate sequence incoporated thus can only be recognized by specific bacterial stains because of their fimbrial lectins. Such systems can be used in antiadhesin therapies to block bacterial colonizations with high selectivity; they can also be used as targeted drug delivery system to empower conventional broad spectrum antibiotics to achieve a selectivity.